United States · FDA National Drug Code directory
Adderall XR
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 54092-391_38ac432b-672e-4dd1-8af5-bea373aa5f3f
- Product NDC
- 54092-391
- Form
- CAPSULE, EXTENDED RELEASE
- Composition / generic term
- Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate and Amphetamine Aspartate
- Labeler
- Takeda Pharmaceuticals America, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20011011
- Source listing expiry
- 20271231
Source-listed ingredients
- DEXTROAMPHETAMINE SULFATE — 7.5 mg/1
- DEXTROAMPHETAMINE SACCHARATE — 7.5 mg/1
- AMPHETAMINE ASPARTATE MONOHYDRATE — 7.5 mg/1
- AMPHETAMINE SULFATE — 7.5 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (54092-391-01) · 54092-391-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →